Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pulmatrix Inc    PULM

PULMATRIX INC (PULM)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
0.4881(c) 0.482(c) 0.4476(c) 0.4534(c) 0.445 Last
2 148 577 1 996 009 2 230 052 656 418 707 881 Volume
+5.22% -1.25% -7.14% +1.30% -1.85% Change
More quotes
Company
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs.It designs and develops inhaled therapeutic... 
More about the company
Latest news on PULMATRIX INC
03/30PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Entry into a Material Definitive Ag..
AQ
03/29PULMATRIX : Announces Pricing Of $15.2 Million Underwritten Public Offering
PR
03/17PULMATRIX : Expects Key Results of Phase 1/1b Trial of Lung Fungus Treatment by ..
AQ
03/14PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Results of Operations and Financial..
AQ
03/13PULMATRIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
03/13PULMATRIX, INC. : Results of Operations and Financial Condition, Financial State..
AQ
03/13PULMATRIX : Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary D..
PR
02/12PULMATRIX : Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole..
PR
02/12PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Regulation FD Disclosure
AQ
02/09PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/20$SVSA 062 CRUSHED .07 UP HETE WE GO!!! 83 MILLION IN ASSETS 4.4 MILLION IN CA.. 
04/18$NSPX 02?! STOCK CANCER PATENT $1 RUN COMING? ur @ the right place RIGHT TIM..
6
04/18$NSPX 02?! STOCK CANCER PATENT $1 RUN COMING? ur @ the right place RIGHT TIM.. 
04/16$NSPX 019?! STOCK CANCER PATENT $1 RUN COMING? ur @ the right place RIGHT TI.. 
04/16$NSPX MM CDEL trying 2 box her in on the ask & bid ??? STOCK CANCER PATEN.. 
More tweets
Qtime:81
News from SeekingAlpha
03/30YOUR DAILY PHARMA SCOOP : Heron Offering, Sorrento Issues Letter To Shareholders.. 
03/29Pulmatrix down 26% premarket on pricing public offering of 23.5M units 
03/26HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am 
03/21Pulmatrix readies equity offering 
03/14Pulmatrix registers $10M equity offering 
Chart PULMATRIX INC
Duration : Period :
Pulmatrix Inc Technical Analysis Chart | PULM | US74584P1030 | 4-Traders
Technical analysis trends PULMATRIX INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Managers
NameTitle
Robert W. Clarke President, Chief Executive Officer & Director
Mark T. Iwicki Chairman
William E. Duke Chief Financial Officer, Treasurer & Secretary
David L. Hava Chief Scientific Officer
James M. Roach Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX INC-67.84%17
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998